Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies

Collins, 2005, Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States, Am J Kidney Dis, 45, A5, 10.1053/j.ajkd.2004.10.009 Van Dijk, 2001, Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries, Nephrol Dial Transplant, 16, 1120, 10.1093/ndt/16.6.1120 Stengel, 2003, Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990–1999, Nephrol Dial Transplant, 18, 1824, 10.1093/ndt/gfg233 US Renal Data System, 2004 Brown, 1994, Comparative mortality from cardiovascular disease in patients with chronic renal failure, Nephrol Dial Transplant, 9, 1136, 10.1093/ndt/9.8.1136 Gupta, 2004, The renal patient with coronary artery disease: current concepts and dilemmas, J Am Coll Cardiol, 44, 1343 Wright, 2002, Acute myocardial infarction and renal dysfunction: a high-risk combination, Ann Intern Med, 137, 563, 10.7326/0003-4819-137-7-200210010-00007 Fellstrom, 2005, Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study, Curr Control Trials Cardiovasc Med, 6, 9, 10.1186/1468-6708-6-9 Wanner, 2005, Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis, N Engl J Med, 353, 238, 10.1056/NEJMoa043545 Antman, 2004, J Am Coll Cardiol, 44, E1, 10.1016/j.jacc.2004.07.014 The SOLVD Investigators, 1991, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501 The SOLVD Investigators, 1992, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions, N Engl J Med, 327, 685, 10.1056/NEJM199209033271003 The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators, 1993, Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure, Lancet, 342, 821 Fox, 2003, Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study), Lancet, 362, 782, 10.1016/S0140-6736(03)14286-9 Kober, 1995, A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group, N Engl J Med, 333, 1670, 10.1056/NEJM199512213332503 Pfeffer, 1992, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators, N Engl J Med, 327, 669, 10.1056/NEJM199209033271001 The Heart Outcomes Prevention Evaluation Study Investigators, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators, N Engl J Med, 342, 145, 10.1056/NEJM200001203420301 Mann, 2001, Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial, Ann Intern Med, 134, 629, 10.7326/0003-4819-134-8-200104170-00007 Tokmakova, 2004, Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study, Circulation, 110, 3667, 10.1161/01.CIR.0000149806.01354.BF Heiat, 2002, Representation of the elderly, women, and minorities in heart failure clinical trials, Arch Intern Med, 162, 1682, 10.1001/archinte.162.15.1682 Berger, 2003, Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction, J Am Coll Cardiol, 42, 201, 10.1016/S0735-1097(03)00572-2 Efrati, 2002, ACE inhibitors and survival of hemodialysis patients, Am J Kidney Dis, 40, 1023, 10.1053/ajkd.2002.36340 McCullough, 2002, Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease, J Renin Angiotensin Aldosterone Syst, 3, 188, 10.3317/jraas.2002.040 Knoll, 2002, Renin–angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients, Am J Med, 112, 110, 10.1016/S0002-9343(01)01068-3 Greenbaum, 2000, Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency, Br J Clin Pharmacol, 49, 23, 10.1046/j.1365-2125.2000.00103.x Sica, 1991, Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency, Clin Pharmacokinet, 20, 420, 10.2165/00003088-199120050-00006 Gehr, 1993, The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients, Eur J Clin Pharmacol, 45, 431, 10.1007/BF00315514 Zannad, 2002, FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics, Fund Clin Pharmacol, 16, 353, 10.1046/j.1472-8206.2002.00127.x Edwards, 1999, On model prespecification in confirmatory randomized studies, Stat Med, 18, 771, 10.1002/(SICI)1097-0258(19990415)18:7<771::AID-SIM80>3.0.CO;2-E